PMID- 10389763
OWN - NLM
STAT- MEDLINE
DCOM- 19990719
LR  - 20190708
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 82
IP  - 2
DP  - 1999 Jul 19
TI  - Regulation of matrix metalloproteinase-2 (MMP-2) by hepatocyte growth 
      factor/scatter factor (HGF/SF) in human glioma cells: HGF/SF enhances MMP-2 
      expression and activation accompanying up-regulation of membrane type-1 MMP.
PG  - 274-81
AB  - Hepatocyte growth factor/scatter factor (HGF/SF) contributes to the malignant 
      progression of human gliomas. We investigated the effect of HGF/SF on matrix 
      metalloproteinase-2 (MMP-2), membrane type 1 matrix metalloproteinase (MT1-MMP) 
      and tissue inhibitors of metalloproteinases (TIMPs), expressions of c-Met/HGF 
      receptor-positive human glioblastoma cells. Treatment of U251 human glioblastoma 
      cells with HGF/SF resulted in enhanced secretion of MMP-2 with an increased level 
      of the active form. This was accompanied by enhanced expression (2.5-fold) of 
      mRNA specific for MMP-2. The stimulatory effect of HGF/SF on MMP-2 expression did 
      not occur in the presence of herbimycin A, a protein tyrosine kinase inhibitor. 
      MT1 -MMP, a cell-surface activator of proMMP-2, was also up-regulated by HGF/SF 
      in a dose-dependent manner. By contrast, the level of TIMP- 1 mRNAs was not 
      altered significantly and that of TIMP-2 was reduced mildly by the HGF/SF 
      treatment, suggesting that HGF/SF may eventually modulate a balance between MMP-2 
      and TIMPs in favor of the proteinase activity in the glioma cell 
      microenvironment. HGF/SF also stimulated MMP-2 expression of other glioblastoma 
      cell lines. Since glioblastomas frequently co-express HGF/SF and its receptor, 
      our results suggest that HGF/SF might contribute to the invasiveness of 
      glioblastoma cells through autocrine induction of MMP-2 expression and 
      activation.
FAU - Hamasuna, R
AU  - Hamasuna R
AD  - Second Department of Pathology, Miyazaki Medical College, Japan.
FAU - Kataoka, H
AU  - Kataoka H
FAU - Moriyama, T
AU  - Moriyama T
FAU - Itoh, H
AU  - Itoh H
FAU - Seiki, M
AU  - Seiki M
FAU - Koono, M
AU  - Koono M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Benzoquinones)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Lactams, Macrocyclic)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Quinones)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Neoplasm)
RN  - 0 (Recombinant Proteins)
RN  - 1W306TDA6S (Rifabutin)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - 70563-58-5 (herbimycin)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 3.4.24.- (Gelatinases)
RN  - EC 3.4.24.- (Matrix Metalloproteinases, Membrane-Associated)
RN  - EC 3.4.24.- (Metalloendopeptidases)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
SB  - IM
MH  - Benzoquinones
MH  - Brain Neoplasms/enzymology/genetics/*pathology
MH  - Disease Progression
MH  - Enzyme Induction/drug effects
MH  - Enzyme Inhibitors/pharmacology
MH  - Epidermal Growth Factor/pharmacology
MH  - Gelatinases/*biosynthesis/genetics
MH  - Gene Expression Regulation, Neoplastic/*drug effects
MH  - Glioblastoma/enzymology/genetics/pathology
MH  - Glioma/enzymology/genetics/*pathology
MH  - Hepatocyte Growth Factor/*pharmacology
MH  - Humans
MH  - Lactams, Macrocyclic
MH  - Matrix Metalloproteinase 2
MH  - Matrix Metalloproteinases, Membrane-Associated
MH  - Metalloendopeptidases/*biosynthesis/genetics
MH  - Neoplasm Invasiveness
MH  - Neoplasm Proteins/*biosynthesis/genetics
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Quinones/pharmacology
MH  - RNA, Messenger/biosynthesis/genetics
MH  - RNA, Neoplasm/biosynthesis/genetics
MH  - Recombinant Proteins/pharmacology
MH  - Rifabutin/analogs & derivatives
MH  - Signal Transduction/drug effects
MH  - Stimulation, Chemical
MH  - Tumor Cells, Cultured
EDAT- 1999/07/02 10:00
MHDA- 2000/06/20 09:00
CRDT- 1999/07/02 10:00
PHST- 1999/07/02 10:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1999/07/02 10:00 [entrez]
AID - 10.1002/(SICI)1097-0215(19990719)82:2<274::AID-IJC19>3.0.CO;2-2 [pii]
AID - 10.1002/(sici)1097-0215(19990719)82:2<274::aid-ijc19>3.0.co;2-2 [doi]
PST - ppublish
SO  - Int J Cancer. 1999 Jul 19;82(2):274-81. doi: 
      10.1002/(sici)1097-0215(19990719)82:2<274::aid-ijc19>3.0.co;2-2.